India Rule 38: Reporting Foreign Regulatory Action Within 15 Days

1. Key takeaways

Under Rule 38(1)(ii) of the Medical Devices Rules, 2017, the holder of an import licence must inform the licensing authority, immediately and in any case within 15 days, of any administrative measures taken abroad because of adverse reactions — namely withdrawal of the device from the market, regulatory restrictions, cancellation of the marketing authorisation, or a declaration that the device fails to meet standards of quality. The triggering authority may be the country of origin, but it may equally be any other country in which the device has been placed on the market, sold or distributed. In parallel, under Rule 38(1)(iii), the authorised agent must stop shipment and sale of the device immediately. The reporting duty and the stop-sale duty therefore run side by side, on different clocks, and neither waits for the other.

• The 15-day reporting window applies to administrative measures taken in any jurisdiction where the device is marketed, not only in the country of origin.
• Four categories trigger the duty: market withdrawal, regulatory restriction, cancellation of marketing authorisation, and a declaration that the device does not meet standards of quality.
• Rule 38(1)(iii) requires the authorised agent to halt shipment and marketing immediately, which is a faster clock than the 15-day report.
• Rule 38(1)(iv) empowers the CLA, after consideration, to issue directions on placing on the market, sale and distribution, including withdrawal from the Indian market within a specified period.
• Rule 38(2) empowers the CLA to direct that an entire batch not be sold or be recalled from the market, including from hospitals.

2. Legal basis

Rule 38 of the MDR 2017 governs the duties that arise when regulatory trouble occurs outside India for a device that holds an Indian import licence. Its structure is sequential: the licence holder reports, the authorised agent stops supply, and the CLA then holds direction-issuing powers over the market. The table below summarises each limb of the rule as written.

Read together, these provisions convert a regulatory setback in any foreign market into an immediate Indian compliance event. The rule does not ask whether the foreign measure was justified, whether an appeal is pending, or whether the company disputes the finding; the mere existence of the administrative measure engages the reporting and stop-shipment duties, and the assessment of consequences belongs to the CLA.

3. Expert insights

Insight one: this is a rule about foreign events creating domestic obligations. The adverse reaction may occur, and the administrative measure may be taken, in the United States, the European Union or China, yet the obligation lands on the Indian licence holder. The provision wires global vigilance directly into the Indian licenceholding: whatever happens to the product anywhere in the world becomes relevant to the Indian authorisation the moment it happens, and the Indian regulator expects to hear about it on the same timetable as the local regulator that acted.

Insight two: the phrase “any other country” is a wide formulation. The duty is not confined to the country of origin and India. If the product is withdrawn or restricted in any single market where it is sold, that action must be reported to the Indian licensing authority. This effectively requires companies to maintain a global regulatory intelligence capability rather than only watching India, because an event in the smallest export market carries the same 15-day consequence as an event in the largest one. A company whose awareness of its own foreign regulatory actions depends on chance emails will not meet this standard reliably.

Insight three: the 15-day report and the immediate stop are two parallel duties. The report has a 15-day window; the halt on shipment and sale is immediate. A company cannot wait until the report is drafted, approved and submitted before pulling the product from supply, because by then the immediate-stop duty has already been breached. The two obligations are measured on different clocks and must be managed by different workstreams that start at the same moment.

Insight four: the rule says “administrative measures”, not “recall”. Market withdrawal, regulatory restriction, cancellation of the authorisation and a declaration of non-conformity with standards of quality — all four count, and the scope is wider than a recall. A restriction short of withdrawal, or a formal finding that the product fails quality standards without any removal from the market, still triggers the reporting duty. Companies that scan only for recalls will systematically miss reportable events, and the four categories should be written into the internal monitoring criteria explicitly.

4. Practical recommendations

• Build a global regulatory action monitoring table: list on separate rows every country where the product has been placed on the market, so that no market is invisible to the Indian compliance process.
• Designate a regulatory owner for each market as the information source, so that every row of the table has a named person responsible for reporting developments.
• Agree an internal notification rule under which any regulatory action in any market is communicated to the regulatory lead of the India project within 24 hours, which preserves the full 15-day window for the formal report.
• Pre-establish the execution workflow for the immediate stop to shipment, so that supply can be halted without waiting for the report to be completed, approved or submitted.
• Record all four trigger categories — withdrawal, restriction, cancellation of authorisation and non-conformity declaration — in the monitoring criteria, and confirm internally that the scope is not limited to recalls.

The monitoring table may look redundant for companies that operate in only a few markets, but it serves the Indian obligation and the company’s duties in every other market at the same time. It is built once and reused everywhere, which is why the effort pays for itself across the whole regulatory portfolio.

5. Verification checklist

• ☐ All countries where the product has been placed on the market have been listed
• ☐ A regulatory owner has been designated as the information source for each market
• ☐ A 24-hour internal notification mechanism has been agreed
• ☐ An execution workflow for the immediate stop to shipment has been pre-established, without waiting for the report
• ☐ The team understands that the four trigger categories are not limited to recalls

Regulatory information verified as of 27 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including India. Our team prepares dossiers to CDSCO expectations, manages SUGAM submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com